



## Exercise of options and PDMR Dealing

November 17, 2021

RNS Number : 7413S

MaxCyte, Inc.

17 November 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

### **Exercise of options, PDMR dealing and Total Voting Rights**

**Gaithersburg, Maryland, November 17, 2021** - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that Doug Doerfler, Chief Executive Officer and Founder of the Company and Amanda Murphy, Chief Financial Officer, have exercised options over 350,000 shares of common stock of \$0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 350,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock"), together with 100,000 shares previously owned by Doug Doerfler, have been sold by Doug Doerfler and Amanda Murphy at a price range between of \$12.08 and \$12.66 per Common Stock ("Sale"). The sold shares represent approximately 10% and 12% of Doug Doerfler's and Amanda Murphy total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Doug Doerfler holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company and Amanda Murphy holds 0 shares of Common Stock. Following the Exercise, Doug Doerfler and Amanda Murphy hold a further 2,516,680 and 1,065,470 options over Common Stock respectively.

#### **Total voting rights**

The 350,000 New Common Stock have been admitted to trading on AIM pursuant to the Block Listing announced by the Company on September 6, 2021. The New Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 101,168,137 shares

of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 100,838,137 and the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 330,000.

**MaxCyte Contacts:**

*US IR Adviser* +1 415-937-5400  
**Gilmartin Group** [ir@maxcyte.com](mailto:ir@maxcyte.com)  
 David Deuchler, CFA

*Nominated Adviser and Joint Corporate Broker* +44 (0)20 7886 2500  
 Panmure Gordon  
 Emma Earl / Freddy Crossley  
 Corporate Broking  
 Rupert Dearden

*UK IR Adviser* +44 (0)203 709 5700  
**Consilium Strategic Communications** [maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)  
 Mary-Jane Elliott  
 Chris Welsh

**About MaxCyte**

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:**

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	a) Doug Doerfler b) Amanda Murphy
<b>2</b>	<b>Reason for the notification</b>	

a)	Position/status	a) Chief Executive Officer b) Chief Financial Officer						
b)	Initial notification/Amendment	Initial Notification						
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>							
a)	Name	MaxCyte, Inc.						
b)	LEI	54930053YHXULRFCU991						
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>							
a)	Description of the financial instrument, type of instrument  Identification code	\$0.01 ordinary shares  US57777K1060						
b)	Nature of the transaction	Exercise of options over Common Stock						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s) per Ordinary Share</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>a) N/A</td> <td>a) 200,000</td> </tr> <tr> <td>b) N/A</td> <td>b) 150,000</td> </tr> </tbody> </table>	Price(s) per Ordinary Share	Volume(s)	a) N/A	a) 200,000	b) N/A	b) 150,000
Price(s) per Ordinary Share	Volume(s)							
a) N/A	a) 200,000							
b) N/A	b) 150,000							
d)	Aggregated information: · Aggregated volume: · Price:	350,000 N/A						
e)	Date of the transaction	12 to 16 November 2021						
f)	Place of the transaction	London Stock Exchange - AIM						

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	a) Doug Doerfler b) Amanda Murphy
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	a) Chief Executive Officer b) Chief Financial Officer
b)	Initial notification/Amendment	Initial Notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	

a)	Name	MaxCyte, Inc.	
b)	LEI	54930053YHXULRFCU991	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	\$0.01 ordinary shares	
	Identification code	US57777K1060	
b)	Nature of the transaction	Sale of Common Stock	
c)	Price(s) and volume(s)	<b>Price(s) per Ordinary Share</b>	<b>Volume(s)</b>
		a) \$12.6573	a) 101,847
		a) \$12.1600	a) 123,263
		a) \$12.0769	a) 74,890
		b) \$12.6572	b) 51,103
		b) \$12.1605	b) 61,591
		b) \$12.0769	b) 37,306
d)	Aggregated information:		
	· Aggregated volume:	450,000	
	· Price:	\$12.2981	
e)	Date of the transaction	12 to 16 November 2021	
f)	Place of the transaction	London Stock Exchange - AIM	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEAXFXFDLFFFA